Table I.

Comparison of patients who received remdesivir within 5 days of onset of symptoms and those who received remdesivir after 5 days of onset of symptoms.^*

Characteristic	Early Remdesivir n = 90 (%)	Late Remdesivir n = 222 (%)	P
Demographic characteristics  Age, median (IQR), ys  Male sex	77 (63–85) 47 (52.2)	67 (56–77) 150 (67.6)	<0.001 0.011
Comorbidities  Chronic pulmonary disease  Hypertension  Chronic heart disease  Diabetes mellitus  Cerebrovascular disease  Chronic renal disease  Solid neoplasm	15 (16.9) 41 (45.6) 38 (42.2) 26 (28.9) 19 (21.1) 6 (6.7) 12 (13.3)	17 (7.7) 105 (47.3) 56 (25.2) 48 (21.6) 15 (6.8) 9 (4.1) 17 (7.7)	0.017 0.780 0.003 0.172 <0.001 0.382 0.118
Charlson Comorbidity Index score, median (IQR)	1 (1–2.75)	1 (0–2)	0.140
Symptoms before admission  Temperature >37.5°C  Cough  Asthenia  Dyspnea  Diarrhea  Myalgias	45 (50) 24 (26.7) 24 (26.7) 39 (43.3) 10 (11.1) 17 (18.9)	169 (76.1) 101 (45.5) 58 (26.1) 96 (43.2) 28 (12.6) 31 (14)	<0.001 0.002 0.922 0.988 0.713 0.275
Clinical features on admission  Temperature >37.5°C  P/F ratio <300  Lymphocytes <800 cells/mm3  Platelets <150 × 103/μL  D-dimer >1000 ng/mL (n = 176)  C-reactive protein mg/dl, median (IQR)  C-reactive protein >5 mg/dL Procalcitonin, median (IQR), ng/mL LDH >250 U/L (n = 229)	45 (50) 41 (45.6) 39 (43.3) 34 (38.2) 21/53 (39.6) 4.7 (2.2–9) 41 (45.6) 0.09 (0.07–1.9) 35/63 (55.6)	169 (76.1–) 124 (55.9–) 104 (46.8–) 53 (24.1–) 27/123 (22) 5.6 (2.6–9.7) 125 (56.3) 0.09 (0.06–0.15) 112/166 (67.5)	<0.001 0.099 0.573 0.013 0.016 0.098 0.085 0.685 0.093
COVID-19 treatment during hospital stay  Corticosteroids  Low-molecular-weight heparin  Plasma  Baricitinib	90 (100) 87 (96.7) 16 (17.8) 8 (8.9)	221 (99.5) 215 (96.8) 44 (19.8) 38 (17.1)	0.524 0.935 0.678 0.063

IQR = interquartile range; LDH = lactate dehydrogenase; P/F ratio = ratio of inspired oxygen to pulse saturation to fraction of inspired oxygen.

^⁎Data are presented as number (percentage) of patients unless otherwise indicated.